What this means
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 40 and over
- Where
- 1 site
The science
- Registered title
- Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
- Trial ID
- NCT06851832 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- What is tested
- Recombinant zoster vaccine(CHO cell)(low adjuvant), Recombinant Zoster Vaccine (CHO cell), Zoster Vaccine, Live, Recombinant Zoster Vaccine (CHO cell), Recombinant Zoster Vaccine (CHO cell) (Adjuvant control), Normal Saline
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
- Ages
- 40 Years to no maximum
- Dates
- First posted Feb 28, 2025 · updated Oct 28, 2026
Registry summary
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
Sites (1)
- Xiangcheng County Center for Disease Control and Prevention, Xuchang, Henan, China